Sinopharm Company Profile

Aggregated data from the web about Sinopharm

Company Name	Sinopharm
Website	https://www.who.int
Snippet	A large multi-country Phase 3 trial has shown that 2 doses,administered at an interval of 21 days, have an efficacy of 79% againstsymptomatic SARS-CoV-2 infection 14 or more days after the second dose. Vaccineefficacy against hospitalization was 79%. The trial was not designed and … See more
Type	state-owned enterprise
Owner	Chinese central government (100%)
Parent	SASAC of the State Council
Founded	1998
Revenue	CN¥247.110 billion (2014)
Key people	Liu Jingzhen (Chairman & Chinese Communist Party Committee Secretary)[1][2]
Net income	CN¥2.705 billion (2014)
Trade name	Sinopharm
Area served	China, exported worldwide
Hanyu Pinyin	Guóyào jítuán
Headquarters	20 Zhichun Road, Haidian District, Beijing, China
Subsidiaries	Sinopharm Industrial Investment (51%), → Sinopharm Group (56.79%), Trad. Chinese Medicine (37.59%), Shyndec Pharma. (41.62%), China National Biotec Group (95%), → Tiantan Biological (53.30%)
Total assets	CN¥199.192 billion (2014)
Total equity	CN¥31.944 billion (2014)
Transcriptions	TranscriptionsStandard MandarinHanyu PinyinGuóyào jítuán
Operating income	CN¥8.758 billion (2014)
Simplified Chinese	国药集团
Traditional Chinese	國藥集團

Have a list of company names and need to update information? Use our Company Search tool.

Please note that Powrbot Inc does not own this content and cannot vouch for its accuracy, we simply aggregate public information for ease of research.

Want to update this profile? Please contact us here with a link to the public source verifying the edit.